ZUMA-12: axicabtagene ciloleucel as a first-line therapy in patients with high-risk LBCL
Sattva Neelapu • 12 Dec 2021
CAPTIVATE: ibrutinib/venetoclax delivers high rates of uMRD in CLL
Constantine Tam • 10 Dec 2019
AATT study final results: allo or auto transplant for consolidation in T-cell lymphoma?
Frontline ibrutinib-FCR for younger CLL patients: Phase II results
Matthew Davids • 20 Jun 2019